Pharma

Your Article Summary

See Latest Articles

Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization
Forest Laboratories, 06/22/09

Forest Laboratories, Inc. announced positive results from two global multi-center Phase III studies of ceftaroline for the treatment of community-acquired bacterial pneumonia. The top-line data in each of the pivotal trials demonstrate that ceftaroline met the primary objective of non-inferiority and achieved high clinical cure rates compared with ceftriaxone in patients with moderate to severe community-acquired bacterial pneumonia requiring hospitalization.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
Clinical Cancer Research, 10/19/09

A Randomized Trial of Doxycycline for Mansonella perstans Infection
New England Journal of Medicine, 10/08/09

Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention
Trials, 10/28/09

See All of Drug Trials